REITLER
BROWN &
ROSENBLATT LLC                                      800 Third Avenue, 21st Floor
- ----------------                                         New York, NY 10022-7604
ATTORNEYS AT LAW                                              Tel (212) 209-3050
                                                              Fax (212) 371-5500


                                     January 24, 2008


VIA ELECTRONIC TRANSMISSION

Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Mail Stop 6010
Attn: Jeffrey Riedler

         RE: ELITE PHARMACEUTICALS, INC. (THE "COMPANY")
             REGISTRATION STATEMENT ON FORM S-3 (FILE NO. 333-145502)

Dear Mr. Riedler:

         On behalf of Elite  Pharmaceuticals,  Inc., a Delaware corporation (the
"Company"),  we hereby file electronically  under the Securities Act of 1933, as
amended (the  "Securities  Act"),  the request of the Company to accelerate  the
effectiveness  of  the   above-referenced   registration   statement  under  the
Securities Act.

         Please contact the undersigned if we may be of assistance.

                                                   Sincerely,

                                                   /s/ Scott Rosenblatt

                                                   Scott Rosenblatt, Esq.

Enclosure

cc:  Bernard Berk


                           Elite Pharmaceuticals, Inc.
                     167 Ludlow Avenue, Northvale, NJ 07647

                                January 24, 2008


Securities and Exchange Commission
100 F Street, NE
Washington DC 20549

               RE:  ELITE PHARMACEUTICALS, INC. (THE "COMPANY")
                    REGISTRATION STATEMENT ON FORM S-3 (FILE NO. 333-145502)

Ladies and Gentlemen:

         The   Company   respectfully   requests   that   the   above-referenced
registration  statement be declared effective at 4:00 pm EST on Friday,  January
25, 2008, or as soon thereafter as reasonably practicable.

         The Company acknowledges that:

               o  should   the   Securities   and   Exchange   Commission   (the
                  "Commission")  or the staff of the  Commission  (the "Staff"),
                  acting  pursuant to  delegated  authority,  declare the filing
                  effective,  it does not foreclose the  Commission  from taking
                  any action with respect to the filing;

               o  the action of the Commission or the Staff,  acting pursuant to
                  delegated authority,  in declaring the filing effective,  does
                  not relieve the Company from its full  responsibility  for the
                  adequacy and accuracy of the disclosure in the filing; and

               o  the Company  may not assert the Staff  comments or this action
                  as a defense in any proceeding  initiated by the Commission or
                  any person  under the  federal  securities  laws of the United
                  States.

                                                  Very truly yours,

                                                  ELITE PHARMACEUTICALS, INC.

                                                  By: /s/ Bernard Berk
                                                     -------------------------
                                                      Bernard Berk
                                                      Chief Executive Officer